Simon edward plyte
Chief Scientific Officer Biomunex Pharmaceuticals
Dr Simon Plyte has over 25 years’ experience in the pharmaceutical industry working in both big Pharma and small Biotech. He has been predominantly involved in the preclinical development of novel drugs (from concept to clinical Phase I) for the treatment of cancer (biologics and chemical entities) and the last 10 years has been focussed on Muli-specific antibodies in immune oncology. He is currently the Chief Scientific Officer at Biomunex Pharmaceuticals in Paris, where his team are predominantly focussed on developing MAIT engagers, a first-in-class innovative approach for the treatment of cancer.
Seminars
Thursday 9th July 2026
MAIT Engagers: A Safer Modality with Large Therapeutic Window for the Treatment of Cancer
2:40 pm
- Novelty: Leverage a highly abundant, underexplored T-cell population to expand the therapeutic window and enable safer immune engagement strategies
- Activity in solid tumour: MAIT engagers avoid Treg activation in solid tumours, preventing immune suppression seen with conventional CD3 engagers
- Safety: MAIT engagers uniquely activate MAIT cells and do not cause cytokine release syndrome, at difference to CD3 engagers
